3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study

Wu, Xiaojun; Liu, Xiaofan; Zhou, Yilu; Yu, Hong; Li, Ruiyun; Zhan, Qingyuan; Ni, Fang; Fang, Shiqiang; Lü, Yang; Ding, Xuhong; Liu, Hailing; Ewing, Rob M.; Jones, Mark G.; Hu, Yi; Nie, Hanxiang; Wang, Yihua

doi:10.1016/s2213-2600(21)00174-0

Cited by 489 publications

(529 citation statements)

References 33 publications

Supporting

Mentioning

423

Contrasting

Unclassified

Order By: Relevance

“…It is important to note that quality of life questionnaires and 6-min walk tests improved over time in studies with repetitive assessments during a 1-year follow-up of either any cause ARDS (23) or SARS (25). A similar evolution has now been reported in long COVID patients (7).…”

mentioning

confidence: 58%

“…Dyspnea limiting daily activities was present in two-thirds of the patients, but unrelated to chest CT opacities or reduced DL CO, which were noted in one fourth of the patients. In a most recent Chinese study on 83 patients evaluated every 3 months up to one year, dyspnea scores, exercise capacity assessed by a 6-min walk distance, DL CO and forced vital capacity improved over time, along with a decrease incidence of abnormal chest CT findings from 78 % at 3 months to 27 % of them at 6 months (7).…”

mentioning

confidence: 94%

See 1 more Smart Citation

Phenotyping long COVID

Naeije¹,

Caravita

2021

Eur Respir J

View full text Add to dashboard Cite

mentioning

confidence: 58%

mentioning

confidence: 94%

Phenotyping long COVID

Naeije¹,

Caravita

2021

Eur Respir J

View full text Add to dashboard Cite

“…In our cohort of competitive athletes' spirometry, the findings did not reveal modifications related to SARS-CoV-2 infection with the only exception of reduced FEV1%. It has been reported that 11% of patients with severe COVID-19, had reduced FVC [7], while FEV1% was significantly lower in patients after severe or critical COVID-19 compared to patients presenting mild to moderate disease [27]. In a recent study, Gervasi and colleagues [4] found a reduction of PEF in professional athletes recovering from previous mild-to-moderate symptomatic SARS-CoV-19 infection.…”

Section: Discussionmentioning

confidence: 97%

“…However, several reports have described prolonged impairment in lung function in post-COVID-19 patients [5,6], with a significant percentage of patients after rehabilitation programs, which still present exertional dyspnea. The altered lung function, observed in some post-COVID-19 patients [6] and persistent ground glass opacity together with a lack of improvement in respiratory function for up to 12 months [7], raise concerns regarding long-term impairment of respiratory system and physical performance. At present, several information regarding myocarditis in young athletes after COVID-19 disease has been described with heterogeneous prevalence, ranging from 0-15% [8], indicating the necessity of further data and standardized screening protocols before a safe return to play.…”

Section: Introductionmentioning

confidence: 99%

Clinical Characteristics, Exercise Capacity and Pulmonary Function in Post-COVID-19 Competitive Athletes

Komici

Bianco

Perrotta

et al. 2021

JCM

View full text Add to dashboard Cite

Background: Limited evidence exists regarding adverse modifications affecting cardiovascular and pulmonary function in physical active adults affected by COVID-19, especially in athletic populations. We aimed to describe the clinical presentation of COVID-19 in a cohort of competitive athletes, as well as spirometry and echocardiography findings and cardio-respiratory performance during exercise. Methods: Twenty-four competitive athletes with COVID-19 were recruited for this study after ending self-isolation and confirmation of negative laboratory results. All athletes underwent clinical evaluation, spirometry, echocardiography and cardiopulmonary exercise testing (CPET). These data were compared to a group of healthy control athletes. Results: Anosmia was the most frequent symptom present in 70.83% patients, followed by myalgia, fatigue and ageusia. The most frequent persisting symptoms were anosmia 11 (45.83%) and ageusia 8 (33.33%). Compared to controls, COVID-19 patients presented lower FEV1%: 97.5 (91.5–108) vs. 109 (106–116) p = 0.007. Peak Oxygen Uptake (VO2) in COVID-19 patients was 50.1 (47.7–51.65) vs. 49 (44.2–52.6) in controls (p = 0.618). Conclusions: Reduced exercise capacity was not identified and pulmonary and cardiovascular function are not impaired during early recovery phase in a population of physical active adults except FEV1 reduction.

show abstract

“…This endothelial dysfunction could potentially be one of the not yet known components of long COVID-19 syndrome [29]: the reduction in vasodilation during exertion could produce fatigue, changes in muscle metabolism and fiber composition, and exercise intolerance.…”

Section: Discussionmentioning

confidence: 99%

Altered Vascular Endothelium-Dependent Responsiveness in Frail Elderly Patients Recovering from COVID-19 Pneumonia: Preliminary Evidence

Paneroni

Pasini

Vitacca

et al. 2021

JCM

View full text Add to dashboard Cite

We evaluated vascular dysfunction with the single passive leg movement test (sPLM) in 22 frail elderly patients at 84 + 31 days after hospitalization for COVID-19 pneumonia, compared to 22 age-, sex- and comorbidity-matched controls (CTRL). At rest, all COVID-19 patients were in stable clinical condition without severe comorbidities. Patients (aged 72 ± 6 years, 73% male) had moderate disability (Barthel index score 77 ± 26), hypoxemia and normocapnia at arterial blood gas analysis and mild pulmonary restriction at spirometry. Values of circulating markers of inflammation (C-reactive protein: CRP; erythrocyte sedimentation rate: ESR) and coagulation (D-dimer) were: 27.13 ± 37.52 mg/dL, 64.24 ± 32.37 mm/1 h and 1043 ± 729 ng/mL, respectively. At rest, femoral artery diameter was similar in COVID-19 and CTRL (p = 0.16). On the contrary, COVID-19 infection deeply impacted blood velocity (p = 0.001) and femoral blood flow (p < 0.0001). After sPLM, peak femoral blood flow was dramatically reduced in COVID-19 compared to CTRL (p = 0.001), as was blood flow ∆peak (p = 0.05) and the area under the curve (p < 0.0001). This altered vascular responsiveness could be one of the unknown components of long COVID-19 syndrome leading to fatigue, changes in muscle metabolism and fibers’ composition, exercise intolerance and increased cardiovascular risk. Impact of specific treatments, such as exercise training, dietary supplements or drugs, should be evaluated.

show abstract

3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study

Cited by 489 publications

References 33 publications

Phenotyping long COVID

Phenotyping long COVID

Clinical Characteristics, Exercise Capacity and Pulmonary Function in Post-COVID-19 Competitive Athletes

Altered Vascular Endothelium-Dependent Responsiveness in Frail Elderly Patients Recovering from COVID-19 Pneumonia: Preliminary Evidence

Contact Info

Product

Resources

About